Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LEIJian-yong ,  YANLu-nan , ZENGYong , WENTian-fu , LIBo , WANGWen-tao , XUMing-qing , YANGJia-yin , WUHong , WEIYong-gang

Department of Liver Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;

Corresponding author：

YANLu-nan, Email: yanlunan688@163.com

Keywords：

Huaier; Sorafenib; Hepatocellular carcinoma; Recurrence

DOI：

10.7507/1007-9424.20140238

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To compare the efficacy and safety of Huaier and Sorafenib in treatment of small hepatocellular carcinoma(HCC)following radical resection. Methods Eighty-two patients with small HCC accepted radical liver resection and then taken Huaier or Sorafenib were collected retrospectively. These patients were divided into Huaier group(51 cases)and Sorafenib group(31 cases)according to the different administration drugs after operation. The baseline characteristics, tumor characteristics, survival rate, tumor recurrence rate, and side effects were compared between two groups. Results ①There were no significant differences on the baseline demographic characteristics, liver function, and tumor characteristics between two groups(P > 0.05).②The overall survival rate and tumor-free survival rate had no significant differences between the Huaier group and the Sorafenib group(P=0.737, P=0.699).③The rate of recurrence or metastasis had no significant difference between the Huaier group and Sorafenib group(37.3% versus 32.3%, P=0.648). The most common site of the recurrence or metastasis was the liver and the lung followed.④There were only 5 cases suffered side effects after taking Huaier and no case needed Huaier discontinuance. However, 11 cases suffered side effects after taking Sorafenib and 3 cases needed Sorafenib discontinuance, and the rate of the side effect in the Sorafenib group was much higher than that in the Huaier group(35.5% versus 9.8%, P=0.026). Conclusion For the small HCC who accepted radical liver resection, Huaier seems to be an effective and safe drug.

Citation： LEIJian-yong, YANLu-nan, ZENGYong, WENTian-fu, LIBo, WANGWen-tao, XUMing-qing, YANGJia-yin, WUHong, WEIYong-gang. Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2014, 21(8): 991-995. doi: 10.7507/1007-9424.20140238 Copy

1.	Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancent, 2003, 362(9399): 1907-1917.
2.	Willatt JM, Francis IR, Novelli PM, et al. Interventional therapies for hepatocellular carcinoma[J]. Cancer Imaging, 2012, 12(1): 79-88.
3.	Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2000[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
4.	Crissien AM, Frenette C. Current management of hepatocellular carcinoma[J]. Gastroenterol Hepatol, 2014, 10(3): 153-161.
5.	荚卫东.根治性肝切除联合索拉非尼治疗肝细胞癌的研究进展[J].世界华人消化杂志, 2012, 20(22): 2019-2023.
6.	刘宝瑞, 王婷婷, 钱晓萍.原发性肝癌分子靶向治疗研究进展[J].世界华人消化杂志, 2009, 17(10): 992-997.
7.	张岚, 任正刚.索拉菲尼治疗肝癌常见不良反应及处理的研究进展[J].中国肿瘤临床, 2013, 40(20): 1268-1271.
8.	吴晖.槐耳颗粒联合化疗栓塞术治疗原发性肝癌96例[J].中国药业, 2014, 23(3): 16-18.
9.	Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003, 38(2): 200-207.
10.	Hasegawa K, Takayama T, Ijichi MA, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial[J]. Hepatology, 2006, 44(4): 891-895.
11.	Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
12.	Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
13.	Gabibbo G, Graxi A. Hepatocellula cancer: optial strategies for screening and surveillance[J]. Dig Dis, 2009, 27(2): 142-147.
14.	於雷, 代智, 周俭, 等.原发性肝癌的分子靶向治疗新进展[J].中华肝脏病杂志, 2009, 17(6): 475-477.
15.	程若川, 王建忠.槐耳的研制及临床应用[J].昆明医学院学报, 2003, 24(1): 106-110.
16.	李敬东, 彭勇, 戴毅, 等.槐耳颗粒联合肝动脉灌注化疗栓塞治疗晚期肝癌的临床研究[J].西部医学, 2010, 22(3): 418-420.
17.	许戈良, 荚卫东, 马金良, 等.槐耳清膏体外抑制血管生成的实验研究[J].中国药理学通报, 2003, 19(12): 1410-1412.
18.	莫斌, 杨家印, 严律南, 等.槐耳颗粒用于肝癌肝移植术后的临床观察[J].四川大学学报:医学版, 2011, 42(5): 739-741.
19.	刘涛.索拉菲尼治疗原发性肝细胞癌的疗效及安全性[J].当代医学, 2013, 19(20): 147-148.
20.	张惠洁, 郭卫东.索拉菲尼在肿瘤治疗中的研究进展[J/CD].中华临床医师杂志:电子版, 2013, 7(1): 137-139.
21.	Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafinib in patients with hepatocellular carcinoma and ChildPugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4(2): 40-44.

1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma[J]. Lancent, 2003, 362(9399): 1907-1917.
2. Willatt JM, Francis IR, Novelli PM, et al. Interventional therapies for hepatocellular carcinoma[J]. Cancer Imaging, 2012, 12(1): 79-88.
3. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics 2000[J]. CA Cancer J Clin, 2005, 55(2): 74-108.
4. Crissien AM, Frenette C. Current management of hepatocellular carcinoma[J]. Gastroenterol Hepatol, 2014, 10(3): 153-161.
5. 荚卫东.根治性肝切除联合索拉非尼治疗肝细胞癌的研究进展[J].世界华人消化杂志, 2012, 20(22): 2019-2023.
6. 刘宝瑞, 王婷婷, 钱晓萍.原发性肝癌分子靶向治疗研究进展[J].世界华人消化杂志, 2009, 17(10): 992-997.
7. 张岚, 任正刚.索拉菲尼治疗肝癌常见不良反应及处理的研究进展[J].中国肿瘤临床, 2013, 40(20): 1268-1271.
8. 吴晖.槐耳颗粒联合化疗栓塞术治疗原发性肝癌96例[J].中国药业, 2014, 23(3): 16-18.
9. Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy[J]. J Hepatol, 2003, 38(2): 200-207.
10. Hasegawa K, Takayama T, Ijichi MA, et al. Uracil-tegafur as an adjuvant for hepatocellular carcinoma: A randomized trial[J]. Hepatology, 2006, 44(4): 891-895.
11. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390.
12. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phaseⅢrandomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34.
13. Gabibbo G, Graxi A. Hepatocellula cancer: optial strategies for screening and surveillance[J]. Dig Dis, 2009, 27(2): 142-147.
14. 於雷, 代智, 周俭, 等.原发性肝癌的分子靶向治疗新进展[J].中华肝脏病杂志, 2009, 17(6): 475-477.
15. 程若川, 王建忠.槐耳的研制及临床应用[J].昆明医学院学报, 2003, 24(1): 106-110.
16. 李敬东, 彭勇, 戴毅, 等.槐耳颗粒联合肝动脉灌注化疗栓塞治疗晚期肝癌的临床研究[J].西部医学, 2010, 22(3): 418-420.
17. 许戈良, 荚卫东, 马金良, 等.槐耳清膏体外抑制血管生成的实验研究[J].中国药理学通报, 2003, 19(12): 1410-1412.
18. 莫斌, 杨家印, 严律南, 等.槐耳颗粒用于肝癌肝移植术后的临床观察[J].四川大学学报:医学版, 2011, 42(5): 739-741.
19. 刘涛.索拉菲尼治疗原发性肝细胞癌的疗效及安全性[J].当代医学, 2013, 19(20): 147-148.
20. 张惠洁, 郭卫东.索拉菲尼在肿瘤治疗中的研究进展[J/CD].中华临床医师杂志:电子版, 2013, 7(1): 137-139.
21. Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and efficacy of sorafinib in patients with hepatocellular carcinoma and ChildPugh A versus B cirrhosis[J]. Gastrointest Cancer Res, 2011, 4(2): 40-44.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Efficacy and Safety of Huaier and Sorafenib in Treatment of Small Hepatocellular Carcinoma Following Radical Resection

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content